Why should a doctor be interested in oral disease?

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 10, 2010, Pages 1483-1493

  Ford, Pauline J ^a   Raphael, Sarah L ^b   Cullinan, Mary P ^c   Jenkins, Alicia J ^d   West, Malcolm J ^a   Seymour, Gregory J ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cardiovascular disease; inflammation; molecular mimicry; periodontal disease

Indexed keywords

HEAT SHOCK PROTEIN 60;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC PERIODONTITIS; ENVIRONMENTAL FACTOR; GINGIVITIS; HEREDITY; HOST SUSCEPTIBILITY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERIODONTAL DISEASE; PHYSICIAN; REVIEW; TOOTH PLAQUE;

ADULT; ANIMALS; BIOFILMS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DENTAL PLAQUE; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; ORAL HEALTH; PERIODONTAL DISEASES;

EID: 77958107762     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.109     Document Type: Review

References (98)

1. Bass CC. The necessity for effective dental health service in cardiology Am. Heart J. 69, 718-719 (1965).
2. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease and risk of coronary heart disease and mortality. BMJ 306(6879), 688-691 (1993).
3. Ajawani S, Matilla KJ, Tilvis RS, Ainamo A. Periodontal diseases and the risk of coronary heart disease and mortality in an aged population. Spec. Care Dent. 23, 125-130 (2003).
4. Holmlund A, Holm G, Lind L. Number of teeth as a predictor of cardiovascular mortality in a cohort of 7,674 subjects followed for 12 years. J. Periodontol. 81(6), 870-876 (2010).
5. Saremi A, Nelson RG, Tulloch-Reid M et al. Periodontal disease and mortality in Type 2 diabetes. Diabetes Care 28(1), 27-32 (2005).
6. Shultis WA, Weil EJ, Looker HC et al. Effect of periodontitis on overt nephropathy and end-stage renal disease in Type 2 diabetes. Diabetes Care 30(2), 306-311 (2007).
7. Kshirsagar AV, Offenbacher S, Moss KL, Barros SP, Beck JD. Antibodies to periodontal organisms are associated with decreased kidney function. The Dental Atherosclerosis Risk In Communities study. Blood Purif. 25(1), 125-132 (2007).
8. Kshirsagar AV, Craig RG, Moss KL et al. Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int. 75(7), 746-751 (2009).
9. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. Clin. Microbiol. Infect. 13(Suppl. 4), 3-10 (2007).
10. Sheiham A, Netuveli GS. Periodontal diseases in Europe. Periodontol. 2000 29, 104-121 (2002).
11. Demmer RT, Papapanou PN. Epidemiologic patterns of chronic and aggressive periodontitis. Periodontol. 2000 53, 28-44 (2010).
12. Cullinan MP, Hamlet SM, Westerman B, Palmer JE, Faddy MJ, Seymour GJ. Acquisition and loss of Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Prevotella intermedia over a 5-year period: effect of a triclosan/copolymer dentifrice. J. Clin. Periodontol. 30(6), 532-541 (2003).
13. Mahanonda R, Pichyangkul S. Toll-like receptors and their role in periodontal health and disease. Periodontol. 2000 43, 41-55 (2007).
14. Seymour GJ, Taylor JJ. Shouts and whispers: an introduction to immunoregulation in periodontal disease. Periodontol. 2000 35, 9-13, 2004.
15. Ohlrich EJ, Cullinan MP, Seymour GJ. The immunopathogenesis of periodontal disease. Aust. Dent. J. 54(Suppl. 1), S2-S10 (2009).
16. Cullinan MP, Ford PJ, Seymour GJ. Periodontal disease and systemic health: current status. Aust. Dent. J. 54(Suppl. 1), S62-S69 (2009).
17. Syrjanen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br. Med. J. 296(6630), 1156-1160 (1988).
18. Grau AJ, Buggle F, Heindl S et al. Recent infection as a risk factor for cerebrovascular ischemia. Stroke 26(3), 373-379 (1995).
19. Libby P. Infammation in atherosclerosis. Nature 420, 868-874 (2002).
20. Hansson GK. Infammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695, (2005).
21. Libby P, Ridker PM, Hansson GK. Infammation in atherosclerosis; from pathophysiology to practice. J. Am. Coll. Cardiol. 54, 2129-2138 (2009).
22. Melnick SL, Shahar E, Folsom AR et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am. J. Med. 95(5), 499-504 (1993).
23. Grau AJ, Buggle F, Ziegler C et al. Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke 28(9), 1724-1729 (1997).
24. Valtonen VV. Role of infections in atherosclerosis. Am. Heart J. 138(5 Pt 2), S431-S433 (1999).
25. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. J. Periodontol. 67(10 Suppl.), 1123-1137 (1996).
26. Hung HC, Willett W, Merchant A, Rosner BA, Ascherio A, Joshipura KJ. Oral health and peripheral arterial disease. Circulation 107(8), 1152-1157 (2003).
27. Desvarieux M, Demmer RT, Rundek T et al. Relationship between periodontal disease, tooth loss, and carotid artery plaque: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Stroke 34(9), 2120-2125 (2003).
28. Jansson L, Lavstedt S, Frithiof L, Theobald H. Relationship between oral health and mortality in cardiovascular diseases. J. Clin. Periodontol. 28(8), 762-768 (2001).
29. Morrison HI, Ellison LF, Taylor GW. Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases. J. Cardiovasc. Risk 6(1), 7-11 (1999).
30. Tuominen R, Reunanen A, Paunio M, Paunio I, Aromaa A. Oral health indicators poorly predict coronary heart disease deaths. J. Dent. Res. 82(9), 713-718 (2003).
31. Howell TH, Ridker PM, Ajani UA, Hennekens CH, Christen WG. Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J. Am. Coll. Cardiol. 37(2), 445-450 (2001).
32. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. JAMA 284(11), 1406-1410 (2000).
33. Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-ana lysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95(5), 559-569 (2003).
34. Khader YS, Albashaireh ZS, Alomari MA. Periodontal diseases and the risk of coronary heart and cerebrovascular diseases: a meta-ana lysis. J. Periodontol. 75(8), 1046-1053 (2004).
35. Humphrey LL, Fu R, Buckley DI, Freeman M, Helfand M. Periodontal disease and coronary heart disease incidence: a systematic review and meta-ana lysis. J. Gen. Intern. Med. 23(12), 2079-2086 (2008).
36. Taylor BA, Tofer GH, Carey HM et al. Full-mouth tooth extraction lowers systemic infammatory and thrombotic markers of cardiovascular risk. J. Dent. Res. 85(1), 74-78 (2006).
37. Hujoel PP, Drangsholt M, Spiekerman C, Derouen TA. Examining the link between coronary heart disease and the elimination of chronic dental infections. J. Am. Dent. Assoc. 132(7), 883-889 (2001).
38. Mercanoglu F, Ofaz H, Oz O et al. Endothelial dysfunction in patients with chronic periodontitis and its improvement after initial periodontal therapy J. Periodontol. 75(12), 1694-1700 (2004).
39. Amar S, Gokce N, Morgan S, Loukideli M, Van Dyke TE, Vita JA. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic infammation. Arterioscler. Thromb. Vasc. Biol. 23(7), 1245-1249 (2003).
40. Ford PJ, Gemmell E, Chan A et al. Infammation, heat shock proteins and periodontal pathogens in atherosclerosis: an immunohistologic study. Oral Microbiol. Immunol. 21(4), 206-211 (2006).
41. Ford PJ, Gemmell E, Timms P, Chan A, Preston FM, Seymour GJ. Anti-P. gingivalis response correlates with atherosclerosis. J. Dent. Res. 86(1), 35-40 (2007)
42. Consensus report. Periodontal diseases: pathogenesis and microbial factors. Ann. Periodontol. 1(1), 926-932 (1996).
43. De Kruif MD, van Gorp EC, Keller TT, Ossewaarde JM, ten Cate H. Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc. Res. 65(2), 317-327 (2005).
44. Campbell LA, Kuo CC, Grayston JT. Chlamydia pneumoniae and cardiovascular disease. Emerg. Infect. Dis. 4(4), 571-579 (1998).
45. Kojima T, Yasui S, Ishikawa I. Distribution of Porphyromonas gingivalis in adult periodontitis patients. J. Periodontol. 64(12), 1231-1237 (1993).
46. Bloemenkamp DG, Mali WP, Visseren FL, van der Graaf Y. Meta-ana lysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design infuence results? Am. Heart J. 145(3), 409-417 (2003).
47. Cochrane M, Pospischil A, Walker P, Gibbs H, Timms P. Discordant detection of Chlamydia pneumoniae in patients with carotid artery disease using polymerase chain reaction, immunofuorescence microscopy and serological methods. Pathology 37(1), 69-75 (2005).
48. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-defcient mice. J. Infect. Dis. 180(1), 238-241 (1999).
49. Lalla E, Lamster IB, Hofmann MA et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 23(8), 1405-1411 (2003).
50. Li L, Messas E, Batista EL Jr, Levine RA, Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-defcient murine model. Circulation 105(7), 861-867 (2002).
51. Campbell JH, Campbell GR. The cell biology of atherosclerosis-new developments. Aust. N. Z. J. Med. 27(4), 497-500 (1997).
52. Polla BS. A role for heat shock proteins in infammation? Immunol. Today 9(5), 134-137 (1988).
53. Fink AL. Chaperone-mediated protein folding. Physiol. Rev. 79(2), 425-449 (1999).
54. Kauffman S. Heat shock proteins and the immune response. Immunol. Today 11(4), 129-136 (1990).
55. Wick G, Perschinka H, Xu Q. Autoimmunity and atherosclerosis. Am. Heart J. 138(5 Pt 2), S444-S449 (1999).
56. Metzler B, Schett G, Kleindienst R et al. Epitope specifcity of anti-heat shock protein 65/60 serum antibodies in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17(3), 536-541 (1997).
57. Zhu J, Quyyumi AA, Rott D et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103(8), 1071-1075 (2001).
58. Mayr M, Metzler B, Kiechl S et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 99(12), 1560-1566 (1999).
59. Ellins E, Shamaei-Tousi A, Steptoe A et al. The relationship between carotid stiffness and circulating levels of heat shock protein 60 in middle-aged men and women. J. Hypertens. 26(12), 2389-2392 (2008).
60. Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 36(2), 303-307 (2000).
61. Welch WJ. Heat shock proteins functioning as molecular chaperones: their roles in normal and stressed cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 339(1289), 327-333 (1993).
62. Hotokezaka H, Hayashida H, Ohara N, Nomaguchi H, Kobayashi K, Yamada T Cloning and sequencing of the GroESL homologue from Porphyromonas gingivalis. Biochim. Biophys. Acta 1219(1), 175-178 (1994).
63. Maeda H, Miyamoto M, Hongyo H, Nagai A, Kurihara H, Murayama Y. Heat shock protein 60 (GroEL) from Porphyromonas gingivalis: molecular cloning and sequence ana lysis of its gene and purifcation of the recombinant protein. FEMS Microbiol. Lett. 119(1-2), 129-135 (1994).
64. Tabeta K, Yamazaki K, Hotokezaka H, Yoshie H, Hara K. Elevated humoral immune response to heat shock protein 60 (HSP60) family in periodontitis patients. Clin. Exp. Immunol. 120(2), 285-293 (2000).
65. Mukhopadhyay S, Good D, Miller RD et al. Identifcation of Chlamydia pneumoniae proteins in the transition from reticulate to elementary body formation. Mol. Cell. Proteomics 5(12), 2311-2318 (2006).
66. Yi Y, Zhong G, Brunham RC. Continuous B-cell epitopes in Chlamydia trachomatis heat shock protein 60. Infect. Immun. 61(3), 1117-1120 (1993).
67. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-ana lysis of randomized controlled trials. JAMA 293(21), 2641-2647 (2005).
68. George J, Shoenfeld Y, Afek A et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler. Thromb. Vasc. Biol. 19(3), 505-510 (1999).
69. Wick G, Perschinka H, Millonig G. Atherosclerosis as an autoimmune disease: an update. Trends Immunol. 22(12), 665-669 (2001).
70. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-defcient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14(1), 133-140 (1994).
71. Sun JB, Czerkinsky C, Holmgren J. Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. Scand. J. Immunol. 66(2-3), 278-286 (2007).
72. Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol. Med. 14(5), 191-198 (2008).
73. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. (2), CD002893 (2003).
74. Czerkinsky C, Russell MW, Lycke N, Lindblad M, Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect. Immun. 57(4), 1072-1077 (1989).
75. + T cells. Immunology 118(3), 311-320 (2006).
76. Cheng X, Yu X, Ding YJ et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol. 127(1), 89-97 (2008).
77. Epstein SE. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ. Res. 90(1), 2-4 (2002).
78. Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17(1), 1-14 (2005).
79. Miyamoto T, Yumoto H, Takahashi Y, Davey M, Gibson FC 3rd, Genco CA. Pathogen-accelerated atherosclerosis occurs early after exposure and can be prevented via immunization. Infect. Immun. 74(2), 1376-1380 (2006).
80. Madan M, Amar S. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic fndings. PLoS One 3(9), e3204 (2008).
81. Xu XH, Shah PK, Faure E et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104(25), 3103-3108 (2001).
82. Gibson FC 3rd, Hong C, Chou HH et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-defcient mice. Circulation 109(22), 2801-2806 (2004).
83. Danesh J, Wheeler JG, Hirschfeld GM et al. C-reactive protein and other circulating markers of infammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397, (2004).
84. Slade GD. Interim ana lysis of validity of periodontitis screening questions in the Australian population. J. Periodontol. 78(7 Suppl.), 1463-1470 (2007).
85. Grossman E, Reiter G, Sturzenburger OP. Six-month study of the effects of a chlorhexidine mouthrinse on gingivitis in adults. J. Periodont. Res. Suppl. 16, 33-43 (1986).
86. Flotra L, Gjermo P, Rolla G, Waerhaug J. A 4-month study on the effect of chlorhexidine mouth washes on 50 soldiers. Scand. J. Dent. Res. 80(1), 10-17 (1972).
87. Overholser CD, Meiller TF, DePaola LG, Minah GE, Niehaus C. Comparative effects of 2 chemotherapeutic mouthrinses on the development of supragingival dental plaque and gingivitis. J. Clin. Periodontol. 17(8), 575-579 (1990).
88. Brecx M, Brownstone E, MacDonald L, Gelskey S, Cheang M. Effcacy of Listerine, Meridol and chlorhexidine mouthrinses as supplements to regular tooth cleaning measures. J. Clin. Periodontol. 19(3), 202-207 (1992).
89. Sharma N, Charles CH, Lynch MC et al. Adjunctive beneft of an essential oil-containing mouthrinse in reducing plaque and gingivitis in patients who brush and foss regularly: a six-month study. J. Am. Dent. Assoc. 135(4), 496-504 (2004).
90. Allen DR, Davies R, Bradshaw B et al. Effcacy of a mouthrinse containing 0.05% cetylpyridinium chloride for the control of plaque and gingivitis: a 6-month clinical study in adults. Compend. Contin. Educ. Dent. 19(2 Suppl.), 20-26 (1998).
91. Lobene RR, Kashket S, Soparkar PM, Shloss J, Sabine ZM. The effect of cetylpridinium chloride on human plaque bacteria and gingivitis. Pharmacol. Ther. Dent. 4(1), 33-47 (1979).
92. Davies RM, Ellwood RP, Davies GM. The effectiveness of a toothpaste containing triclosan and polyvinyl-methyl ether maleic acid copolymer in improving plaque control and gingival health: a systematic review. J. Clin. Periodontol. 31(12), 1029-1033 (2004).
93. Gunsolley JC. A meta-ana lysis of six-month studies of antiplaque and antigingivitis agents. J. Am. Dent. Assoc. 137(12), 1649-1657 (2006).
94. Blinkhorn A, Bartold PM, Cullinan MP et al. Is there a role for triclosan/copolymer toothpaste in the management of periodontal disease? Br. Dent. J. 207(3), 117-125 (2009).
95. Axelsson P, Nystrom B, Lindhe J. The long-term effect of a plaque control program on tooth mortality, caries and periodontal disease in adults. Results after 30 years of maintenance. J. Clin. Periodontol. 31(9), 749-757 (2004).
96. Ramfjord SP, Knowles JW, Nissle RR, Shick RA, Burgett FG. Longitudinal study of periodontal therapy J. Periodontol. 44(2), 66-77 (1973).
97. Suomi JD, Greene JC, Vermillion JR, Doyle J, Chang JJ, Leatherwood EC. The effect of controlled oral hygiene procedures on the progression of periddontal disease in adults: results after third and fnal year. J. Periodontol. 42(3), 152-160 (1971).
98. Offenbacher S, Beck JD, Moss K et al. Results from the Periodontitis and Vascular Events (PAVE) study: a pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease. J. Periodontol. 80(2), 190-201 (2009).